Physician profile
Michel Velez
NPI 1518132570
$927,274.58
in general payments reported to CMS, 2019-2025
72 companies · $105K in 2025
The $105K reported for 2025 was more than what 98% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $96K · 2020: $57K · 2021: $142K · 2022: $144K · 2023: $255K · 2024: $129K · 2025: $105K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $358K · Travel and Lodging: $72K · Consulting Fee: $43K · Food and Beverage: $14K · Long Term Medical Supply Or Device Loan: $716 · Education: $329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $357,880.00 |
| Travel and Lodging | $72,452.62 |
| Consulting Fee | $42,547.25 |
| Food and Beverage | $14,138.75 |
| Long Term Medical Supply Or Device Loan | $715.75 |
| Education | $328.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $284,559.92 | 2019-2025 | Nerlynx |
| Seagen INC. | $193,360.36 | 2019-2025 | Tukysa, Padcev, Adcetris |
| Lilly USA, LLC | $150,466.47 | 2019-2025 | Verzenio, Jaypirca |
| Stemline Therapeutics INC. | $118,867.12 | 2023-2025 | Orserdu |
| Merck Sharp & Dohme LLC | $58,545.06 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $33,523.63 | 2020-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $29,041.36 | 2019-2025 | Enhertu, Datroway, Tagrisso |
| Astellas Pharma US INC | $14,091.01 | 2020-2025 | Padcev, Xospata, Xtandi |
| Pfizer INC. | $11,674.86 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $5,575.55 | 2022-2024 | Tazverik, Onivyde, Somatuline Depot |
| Novartis Pharmaceuticals Corporation | $5,523.99 | 2019-2025 | Kisqali, Piqray |
| Tersera Therapeutics LLC | $5,309.61 | 2022-2024 | Zoladex |
| Eli Lilly Export S.A. Puerto Rico Branch | $5,274.44 | 2024 | Verzenio |
| Regeneron Healthcare Solutions, INC. | $2,416.62 | 2019-2025 | Libtayo |
| Janssen Biotech, INC. | $889.29 | 2019-2025 | Talvey, Darzalex, Tecvayli |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $690.33 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Amgen INC. | $665.55 | 2019-2025 | Kyprolis, Blincyto, Lumakras |
| Genentech USA, INC. | $510.82 | 2019-2025 | Polivy, Phesgo, Alecensa |
| Eisai INC. | $464.39 | 2019-2025 | |
| Celgene Corporation | $428.21 | 2019-2025 | Reblozyl, Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $426.92 | 2019-2025 | Fruzaqla, Ninlaro, Iclusig |
| Genzyme Corporation | $422.00 | 2019-2025 | |
| Abbvie INC. | $412.48 | 2019-2025 | Venclexta |
| Glaxosmithkline, LLC. | $321.89 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Caris Mpi, INC. | $313.87 | 2025 | Mi Cancer Seek |
| Tempus Ai, INC | $258.96 | 2024-2025 | Xt Cdx |
| Incyte Corporation | $253.62 | 2019-2025 | Jakafi, Zynyz, Monjuvi |
| Bayer Healthcare Pharmaceuticals INC. | $228.92 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.78 | 2020-2025 | |
| Kite Pharma, INC. | $203.12 | 2021-2022 | |
| Athenex Pharmaceutical Division, LLC | $175.00 | 2020 | |
| Array Biopharma INC | $173.75 | 2021-2025 | Braftovi, Mektovi, Tukysa |
| Adaptive Biotechnologies Corporation | $157.91 | 2022-2025 | Clonoseq |
| Gilead Sciences, INC. | $146.30 | 2021-2025 | Trodelvy |
| Csl Behring | $109.76 | 2021-2025 | Hemgenix |
| Rigel Pharmaceuticals, INC. | $107.27 | 2022-2024 | Tavalisse, Rezlidhia |
| Jazz Pharmaceuticals INC. | $105.08 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2022 | |
| Novocure INC. | $88.55 | 2024-2025 | Optune Lua (Novottf-200t), Optune Gio |
| Sobi, INC | $77.11 | 2022-2025 | |
| Emd Serono, INC. | $71.19 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $70.43 | 2022-2024 | Givlaari |
| Morphosys, US INC. | $69.62 | 2021-2022 | |
| Adc Therapeutics America, INC. | $69.38 | 2024-2025 | |
| G1 Therapeutics, INC. | $59.98 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $59.62 | 2022 | |
| Legend Biotech USA INC. | $52.80 | 2024 | |
| Beone Medicines USA, INC. | $51.86 | 2025 | Tevimbra |
| Alexion Pharmaceuticals, INC. | $50.11 | 2022-2025 | Ultomiris |
| Deciphera Pharmaceuticals INC. | $50.03 | 2024 | Qinlock, Tgct |
| Myriad Genetic Laboratories, INC. | $45.95 | 2022-2024 | Myrisk |
| Taiho Oncology, INC. | $43.69 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $42.25 | 2022 | |
| Myovant Sciences INC. | $38.32 | 2022 | |
| Apellis Pharmaceuticals, INC. | $29.17 | 2021 | |
| Karyopharm Therapeutics INC. | $28.76 | 2021 | |
| Recordati_rare_diseases_inc. | $24.06 | 2024 | Sylvant |
| Tolmar, INC. | $24.02 | 2023 | |
| Eusa Pharma (US) LLC | $23.25 | 2022 | |
| Servier Pharmaceuticals LLC | $22.13 | 2025 | |
| Geron Corporation | $19.14 | 2025 | Rytelo |
| Global Blood Therapeutics, INC. | $18.05 | 2022 | |
| Agios Pharmaceuticals, INC. | $17.52 | 2022 | |
| Beigene USA, INC. | $17.14 | 2022 | |
| Sumitomo Pharma America, INC. | $16.98 | 2024 | Orgovyx |
| Aveo Pharmaceuticals, INC. | $16.69 | 2022 | |
| Heron Therapeutics, INC. | $14.99 | 2022 | |
| Dova Pharmaceuticals | $14.63 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.89 | 2021 | |
| Janssen Scientific Affairs, LLC | $12.10 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,060.16 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michel Velez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.